Blood Samples Collected to Study a Blood Test for Cancer
Collects blood from healthy adults and people with cancer or liver disease.
Key facts
- Who runs it
- Helio Genomics
- Where
- Coon Rapids, Dallas, Fridley, Memphis, Minneapolis, Redondo Beach, and Richardson, United StatesSee the 7 sites
- Trial code
- Registry title
- Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
- Status
- Recruiting
- People taking part
- 1,200 people, planned
- Started
- 21 May 2019
- Expected to end
- Jan 2028
- Type of study
- Observational
- Treatments tested
- Multi-analyte Blood Test
- Record updated
- 10 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with cancer, cancer in remission, a benign (non-cancer) disease, or healthy volunteers. Blood samples are collected for research on blood tests.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Cancer, cancer in remission, or a benign disease such as benign tumor, diabetes, liver cirrhosis, chronic hepatitis B or C, or COPD. Healthy volunteers can also join.
Main reasons for not taking part
- Cannot sign the informed consent form
- Already gave 50 mL of blood in the last 8 weeks
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- 2.1.1 Age 18 years or older
- 2.1.2 A diagnosis of cancer, cancer remission, benign disease (benign tumor, diabetes, liver cirrhosis, chronic hepatitis B or hepatitis C virus infection, Chronic obstructive pulmonary disease, etc.) or apparently healthy volunteers.
Who cannot take part
- 2.2.1 Patients that are unwilling or unable to sign the Informed Consent Form will be excluded
- 2.2.2 Approximately 50 mL of blood will be drawn from participants within an 8-week period under this protocol. Patients that have already given 50 mL of blood within this time frame will be excluded
Where in United States
- Allina Health, Virginia Piper Cancer InstituteCoon Rapids, United StatesContact: Kathryn GruetzmanTaking people
- Liver Center of TexasDallas, United StatesContact: Ariela MorenoTaking people
- Virginia Piper Cancer Institute Mercy Hospital-Unity CampusFridley, United StatesContact: Lynne SchroederTaking people
- Methodist LeBonheur HealthcareMemphis, United StatesContact: Carol JonesTaking people
- VPCI Oncology ResearchMinneapolis, United StatesContact: Kelsey FroemmingTaking people
- Torrance Memorial Physician Network - Cancer CareRedondo Beach, United StatesContact: Clinical Operations ManagerNo longer taking part
- Methodist HospitalRichardson, United StatesContact: Araceli TorresTaking people
About the trial
What the trial wants to find out
To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benign conditions that may induce false positive or false negative results, and iii) defining the effects of potential interfering substances, such as chemotherapy drugs.
Treatments tested
- Multi-analyte Blood Test
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
- Plain-language title
- Blood Samples Collected to Study a Blood Test for CancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 10 July 2026